LR Health & Beauty Celebrates Its 40th Anniversary
8.1.2025 15:04:00 CET | Business Wire | Press release
Social Commerce Company has been giving sales partners and customers a better quality of life with high-quality product solutions for four decades
The Social Commerce Company LR Health & Beauty is looking back on 40 years of company history this year. The company, which was founded in 1985, has developed into a global player in the direct selling industry in recent years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108836518/en/

LR Headquarters (Photo: Business Wire)
LR Health & Beauty has been setting innovative trends in the nutritional supplements and cosmetics sector for 40 years. The unique selling point: The products are sold by independent sales partners who earn an additional income by recommending products and setting up their own business. "LR stands for quality, innovation and a strong people business that offers an attractive business model to people who want more flexibility, more self-fulfilment and financial independence," explains CEO Dr. Andreas Laabs. "We are proud of the past years and thank our partners, customers and employees who have made this success possible."
Product solutions and business model at the cutting edge
The aim of the Ahlen-based direct selling company is to set new standards in the future, which will contribute to the further growth of the LR Group. LR Health & Beauty laid important foundations for this in 2024, both in terms of products and sales: in April, the Ahlen-based company launched the “LR Health Mission” intestinal metabolism treatment. The new decorative cosmetics line "LR ZEITGARD Signature" followed in September. Both launches will go down in LR history as two of the five most successful launches.
In terms of the business model, LR offers its sales partners a regulated, performance-based income if they meet the qualification criteria with the restructuring of the career plan in October 2024. This gives the LR partnership more security on the path to independence.
Four decades of success set standards for the future
In the course of its company history, LR has achieved numerous milestones. The company's most significant successes include the start of sales of nutritional supplements in 2000 and the success of the best-selling Aloe Vera Drinking Gel in 2002. In the same year, the new Ahlen headquarters on Kruppstraße were opened. Another highlight was the entry in the Guinness Book of Records (formation of the LR logo with 265 VW Polos; 2008) and the founding of the children's charity LR Global Kids Fund in 2009.
In 2015, the company was named the best European direct selling company of the year. The opening of the state-of-the-art aloe vera production facility followed in 2018, followed by the receipt of the "Business Award of the City of Ahlen" in 2019. With the introduction of the "Zeitgard Pro Cosmetic Device" in 2022, the intestinal metabolism treatment "LR Health Mission" in 2024 and the make-up line "ZEITGARD Signature", LR continues its success story.
One person who remembers these special events well is Managing Director Thomas Heursen. He started as an LR sales partner in 1990, quickly reached the career level of orgaleader and switched to the corporate side two years later. Thomas Heursen knows the LR business like no other and explains what LR's recipe for success is: "LR is always on the move and continues to develop without forgetting its roots. Close cooperation with our sales partners is important to us. We have successfully implemented this in recent years. With our product solutions and a business model that is in tune with the times, we are creating the ideal conditions for our partnership with LR to be as successful as possible."
LR Health & Beauty
The LR Group successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108836518/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom